Vaccinated in Tel Aviv, the capital of Israel. AFP
A study by the pharmaceutical company Pfizer on its vaccine in Israel is going well. The results are steadily coming and promising, according to a Reuters report.
About 3.5 million people have now been vaccinated in part or in full, and in short the majority of adults in the country will be fully vaccinated.
The results show a marked reduction in illness in the elderly and people at risk, the groups that were first vaccinated.
In the age group 53 years and older, the number of cases of the virus has decreased by 39%, hospital admissions reduced by 39% and serious illnesses reduced by 29%, in the period from mid-January to February 6, according to Eran Segal, a statistician at the Wizmann Institute of Science in Rehovot, Israel.
Looking at people under 60 years of age, the number of cases of the virus during the same period has decreased by 15% but hospital admissions increased by 15% and serious illness increased u m 25%. This group has not been vaccinated to the same extent.
The Pfizer study in Israel is a so-called fourth phase study, which provides information on the effectiveness of the vaccine in real situations, and not only in isolated experiments on laboratories. It is similar to the study that Kári Stefánsson and the Icelandic government tried to get Pfizer to carry out in this country, without success.
The epidemic is not over Despite the vaccination campaign, the epidemic is less than complete in the country. According to a Reuters article, Israelis now have lower expectations than before that this will happen in the near future, as the number of cases has increased, as in many other places in recent weeks and months.
Very strict assembly restrictions are in force in the country for the third time, but it has been difficult to control the spread, which is due to the rapid spread of the British variant of the virus. On the bright side, however, the Pfizer and BioNTech vaccines seem to work well against the variant.
“We have seen the same activity so far, about 90 – 95%, in the British variant, “says Hezi Levi, Secretary General of the Israeli Ministry of Health. “However, it is still too early to tell, because we have only completed one week of the second vaccination,” he says. “Then nothing can be said about the South African variety yet.”